Gut microbiota and microbiota-derived metabolites in colorectal cancer: enemy or friend

World J Microbiol Biotechnol. 2023 Sep 1;39(11):291. doi: 10.1007/s11274-023-03742-w.

Abstract

Colorectal cancer (CRC) is a highly prevalent gastrointestinal cancer worldwide. Recent research has shown that the gut microbiota plays a significant role in the development of CRC. There is mounting evidence supporting the crucial contributions of bacteria-derived toxins and metabolites to cancer-related inflammation, immune imbalances, and the response to therapy. Besides, some gut microbiota and microbiota-derived metabolites have protective effects against CRC. This review aims to summarize the current studies on the effects and mechanisms of gut microbiota and microbiota-produced metabolites in the initiation, progression, and drug sensitivity/resistance of CRC. Additionally, we explore the clinical implications and future prospects of utilizing gut microbiota as innovative approaches for preventing and treating CRC.

Keywords: Cancer immunity; Cancer metabolism; Colorectal cancer; Gut microbiota; Inflammation.

Publication types

  • Review

MeSH terms

  • Colorectal Neoplasms*
  • Friends
  • Gastrointestinal Microbiome*
  • Humans
  • Inflammation
  • Microbiota*